Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,756
datasets available to search
ShareScore release 0.9.0
Dataset results
2,756 results for “Head and neck”
Dataset related to article "Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group"
<p>This record contains raw data related to article "Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group"</p> <p><strong>Objectives: </strong>The role of radiotherapy (RT) for oligometastases is currently established in different oncological settings but data on salivary gland cancer (SGC) are lacking. We evaluated the role of RT in oligometastatic SGC patients, focusing on stereotactic body radiation therapy (SBRT).</p> <p><strong>Materials and methods: </strong>We performed a retrospective, multicentric study of oligometastatic SGC treated with palliative RT or SBRT. Endpoints included response evaluation and local control (LC).</p> <p><strong>Results: </strong>Between 2006 and 2016, 64 patients were collected from 9 Italian Cancer Centers, on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Working Group. 37 patients (57.8%) were suffering from adenoid cystic carcinoma (ACC) and 27 patients (42.2%) had non-ACC. Thirty-four patients underwent palliative RT (53,1%), and 30 received SBRT (46,9%). Most common metastatic sites were bone for palliative RT and lung for SBRT. Among patients treated with SBRT, an objective response or a stability was observed in all treated lesions. After a median follow-up of 29.2 months (range 2.3-117.1), LC at 12 months was 57.5% for patients treated with SBRT and was higher in ACC subgroup.</p> <p><strong>Conclusion: </strong>We confirmed the potential role of SBRT in the management of oligometastatic SGC patients to control limited burden of disease considering the absence of effective systemic therapies.</p>
Dataset related to article "Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer"
<p>This record contains raw data related to article "Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer"</p> <p><strong>Introduction: </strong>Recently major efforts have been made to define the oligometastatic setting, but for head and neck cancer (HNC) limited data are available. We aimed to evaluate outcome of oligometastatic HNC treated with Stereotactic body radiotherapy (SBRT) as metastasis-directed therapy.</p> <p><strong>Materials and methods: </strong>We analyzed patients treated with SBRT on a maximum of five oligometastases from HNC, in up to two organs. Concomitant treatment was allowed. End points were toxicity, local control of treated metastases (LC), progression-free survival (PFS) and overall survival (OS).</p> <p><strong>Results: </strong>48 consecutive patients and 71 lesions were treated. With a follow-up of 20.2 months, most common primary tumors were larynx (29.2%) and salivary glands (29.2%), while common site of metastases was lung (59.1%). Median dose was 48 Gy (21-75) in 3-8 fractions. Treatment was well tolerated, with two patients reporting mild pain and nausea. LC rates at 1 and 2 years were 83.1% and 70.2%. Previous local therapy (HR 4.97; p = 0.002), oligoprogression (HR 4.07; p = 0.031) and untreated metastases (HR 4.19; p = 0.027) were associated with worse LC. PFS at 1 and 2 years were 42.2% and 20.0%. Increasing age (HR 1.03; p = 0.010), non-adenoid cystic carcinoma (HR 2.57; p = 0.034) and non-lung metastases (HR 2.20; p = 0.025) were associated with worse PFS. One- and 2-years OS were 81.0% and 67.1%. Worse performance status (HR 2.91; p = 0.049), non-salivary primary (HR 19.9; p = 0.005), non-lung metastases (HR 2.96; p = 0.040) were correlated with inferior OS.</p> <p><strong>Conclusions: </strong>SBRT can be considered a safe metastasis-directed therapy in oligometastatic HNC. Efficacy of the treatment seems to be higher when administered upfront in the management of metastatic disease; however, selection of patients need to be improved due to the relevant risk of appearance of new metastatic site after SBRT.</p>
Head-Neck-PET-CT combined GTVs 2D images
<p>This dataset contains 2D images of the combined Gross Tumour Volumes (GTVs) of a Head and Neck cancer public dataset created from four different institutions in Canada. 298 images were created by using the CT and the combined GTV masks extracted from the RTSTRUCTs associated with the patient study. The dataset was orginally collected from https://wiki.cancerimagingarchive.net/display/Public/Head-Neck-PET-CT into an Orthanc server. Patient studies were then processed into 3d numpy arrays. The central slices representing the slice with the highest number of contoured pixels were selected and extracted into 2d numpy arrays. </p>
Dataset related to article "An approach to evaluate the quality of radiological reports in Head and Neck cancer loco-regional staging: experience of two Academic Hospitals "
<p>This record contains raw data related to article “An approach to evaluate the quality of radiological reports in Head and Neck cancer loco-regional staging: experience of two Academic Hospitals"</p> <p>Abstract</p> <p><strong>Objectives: </strong> To evaluate the quality of the reports of loco-regional staging computed tomography (CT) or magnetic resonance imaging (MRI) in head and neck (H&N) cancer.</p> <p><strong>Methods: </strong> Consecutive reports of staging CT and MRI of all H&N cancer cases from 2018 to 2020 were collected. We created lists of quality indicators for tumor (T) for each district and for node (N). We marked these as 0 or 1 in the report calculating a report score (RS) and a maximum sum (MS) of each list. Two radiologists and two otolaryngologists in consensus classified reports as low quality (LQ) if the RS fell in the percentage range 0-59% of MS and as high quality (HQ) if it fell in the range 60-100%, annotating technique and district. We evaluated the distribution of reports in these categories.</p> <p><strong>Results: </strong> Two hundred thirty-seven reports (97 CT and 140 MRI) of 95 oral cavity, 52 laryngeal, 47 oropharyngeal, 19 hypo-pharyngeal, 14 parotid, and 10 nasopharyngeal cancers were included. Sixty-six percent of all the reports were LQ for T, 66% out of all the MRI reports, and 65% out of all CT reports were LQ. Eight-five percent of reports were HQ for N, 85% out of all the MRI reports, and 82% out of all CT reports were HQ. Reports of oral cavity, oro-nasopharynx, and parotid were LQ, respectively, in 76%, 73%, 100% and 92 out of cases.</p> <p><strong>Conclusion: </strong> Reports of staging CT/MRI in H&N cancer were LQ for T description and HQ for N description.</p>
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
ClinicalTrials.gov study NCT00095641. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck
ClinicalTrials.gov study NCT00363441. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine
ClinicalTrials.gov study NCT01288625. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT01491139. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT02254018. IPD Sharing: NO. Countries: 0. Publications: 0.
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
ClinicalTrials.gov study NCT02254044. IPD Sharing: Not stated. Countries: 0. Publications: 0.
CCT2 promotes the proliferation and migration of head and neck squamous cell carcinoma via activating PI3K/AKT pathway
GEO Series GSE195850. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
human head and neck squamous cell carcinoma (HNSCC) to compare different tissue dissociation methods
GEO Series GSE243361. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
Effect of depletion of HuR on gene expression in mouse head and neck squamous cell carcinoma (mHNSCC) cells
GEO Series GSE227029. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide Scan for Methylation Profiles in head and Neck Cancer
GEO Series GSE67114. Homo sapiens. 8 samples. Type: Methylation profiling by genome tiling array.
Integrative multi-omics analyses identify molecular subtypes of head and neck squamous cell carcinoma with distinct therapeutic vulnerabilities
GEO Series GSE248855. Homo sapiens. 13 samples. Type: Expression profiling by high throughput sequencing.
Mapping EGFR-mediated local invasion and response to Cetuximab in head and neck cancer
GEO Series GSE273463. Homo sapiens. 40 samples. Type: Expression profiling by high throughput sequencing.
Radiosensitizing effect of THBS1 knockdown in radioresistant head and neck carcinoma cell lines
GEO Series GSE305473. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model]
GEO Series GSE248154. Mus musculus. 19 samples. Type: Expression profiling by high throughput sequencing.
FADD Functions as an Oncogene in Chr11q13.3 Amplified Head and Neck Squamous Cell Carcinoma
GEO Series GSE289740. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
Identification of genes with altered expression in head and neck cancer
GEO Series GSE83519. Homo sapiens. 44 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.